Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma

Lung Cancer

Volumn 55, Issue 1, 2007, Pages 115-121

  Tsurutani, Junji ^a,c   Steinberg, Seth M ^a   Ballas, Marc ^a   Robertson, Matthew ^a   LoPiccolo, Jaclyn ^a   Soda, Hiroshi ^c   Kohno, Shigeru ^c   Egilsson, Valgardur ^b   Dennis, Phillip A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Akt; Bronchioloalveolar carcinoma; NSCLC; Prognostic factor; Smoking

Indexed keywords

PROTEIN KINASE B;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COCHRAN ARMITAGE TEST; ENZYME ACTIVATION; FEMALE; HAZARD RATIO; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG ALVEOLUS CELL CARCINOMA; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE; SMOKING; STAINING; TREND STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 33845944849     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.09.026     Document Type: Article

References (35)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics. CA Cancer J Clin 55 1 (2005) 10-30
2. Scagliotti G.V., Smit E., Bosquee L., O'Brien M., Ardizzoni A., Zatloukal P., et al. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer 50 1 (2005) 91-96
3. West H.L., Crowley J.J., Vance R.B., Franklin W.A., Livingston R.B., Dakhil S.R., et al. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol 16 7 (2005) 1076-1080
4. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21 12 (2003) 2237-2246 [corrected]
5. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
6. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 16 (2003) 2149-2158
7. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 6 (2004) 1103-1109
8. Brognard J., Clark A.S., Ni Y., and Dennis P.A. Akt/protein kinase b is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61 10 (2001) 3986-3997
9. West K.A., Brognard J., Clark A.S., Linnoila I.R., Yang X., Swain S.M., et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 111 1 (2003) 81-90
10. West K.A., Linnoila I.R., Belinsky S.A., Harris C.C., and Dennis P.A. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res 64 2 (2004) 446-451
11. Tsurutani J., Castillo S.S., Brognard J., Granville C.A., Zhang C., Gills J.J., et al. Tobacco components stimulate Akt-dependent proliferation and NF{kappa}B-dependent survival in lung cancer cells. Carcinogenesis 24 (2005)
12. Tsurutani J., West K.A., Sayyah J., Gills J.J., and Dennis P.A. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65 18 (2005) 8423-8432
13. Tsurutani J., Fukuoka J., Tsurutani H., Shih J.H., Hewitt S.M., Travis W.D., et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24 2 (2006) 306-314
14. Agresti A. Categorical data analysis (1990), John Wiley and Sons, New York p. 100-2
15. Kaplan E., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consierations. Cancer Chem Rep 50 (1966) 163-170
17. Cox D. Regression models and life tables. J R Stat Soc (B) 34 (1972) 187-202
18. Matthews D.E., and Farewell V.T. Using and understanding medical statistics (1996), Basel, Karger
19. Simon R., and Altman D.G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69 6 (1994) 979-985
20. Travis W.D.C.T., Corin B., Shimosato Y., Brambilla E., and Sobin L.H. World health organization: histological typing of lung and pleural tumors (1999), Springer, Berlin
21. Altomare D.A., and Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24 50 (2005) 7455-7464
22. Cappuzzo F., Magrini E., Ceresoli G.L., Bartolini S., Rossi E., Ludovini V., et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96 15 (2004) 1133-1141
23. Ringel M.D., Hayre N., Saito J., Saunier B., Schuppert F., Burch H., et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61 16 (2001) 6105-6111
24. Mills G.B., Lu Y., Fang X., Wang H., Eder A., Mao M., et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 5 Suppl. 16 (2001) 125-141
25. Risinger J.I., Hayes K., Maxwell G.L., Carney M.E., Dodge R.K., Barrett J.C., et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 4 12 (1998) 3005-3010
26. Guedj N., Couvelard A., Arcangeli G., Dubois S., Thabut G., Leseche G., et al. Angiogenesis and extracellular matrix remodelling in bronchioloalveolar carcinomas: distinctive patterns in mucinous and non-mucinous tumours. Histopathology 44 3 (2004) 251-256
27. Erman M., Grunenwald D., Penault-Llorca F., Grenier J., Besse B., Validire P., et al. Epidermal growth factor receptor HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. Lung Cancer 47 3 (2005) 315-323
28. Marchetti A., Pellegrini S., Bertacca G., Buttitta F., Gaeta P., Carnicelli V., et al. FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas correlations with clinicopathological data and K-ras mutations. J Pathol 184 3 (1998) 240-246
29. Wen S., Stolarov J., Myers M.P., Su J.D., Wigler M.H., Tonks N.K., et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 98 8 (2001) 4622-4627
30. Zhou B.P., Hu M.C., Miller S.A., Yu Z., Xia W., Lin S.Y., et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275 11 (2000) 8027-8031
31. Okano J., Gaslightwala I., Birnbaum M.J., Rustgi A.K., and Nakagawa H. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation in esophageal cancer cells. J Biol Chem (2000)
32. Mayo L.D., and Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98 20 (2001) 11598-11603
33. Zhou M., Gu L., Findley H.W., Jiang R., and Woods W.G. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 63 19 (2003) 6357-6362
34. Dumont P., Gasser B., Rouge C., Massard G., and Wihlm J.M. Bronchoalveolar carcinoma: histopathologic study of evolution in a series of 105 surgically treated patients. Chest 113 2 (1998) 391-395
35. Lin D.M., Ma Y., Zheng S., Liu X.Y., Zou S.M., and Wei W.Q. Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma. Histol Histopathol 21 6 (2006) 627-632